tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of James Edwardes Jones, 10 are a HOLD (17.24%), 45 are a BUY (77.59%), 3 are a SELL (5.17%).
Analyst James Edwardes Jones, currently employed at RBC, carries an average stock price target met ratio of 34.54% that have a potential upside of 26.69% achieved within 83 days. Previously, James Edwardes Jones worked at OPPENHEIMER.
James Edwardes Jones’s has documented 105 price targets and ratings displayed on 18 stocks. The coverage is on Consumer Defensive, Healthcare sectors.
Most recent stock forecast was given on PLRX, Pliant Therapeutics at 10-Aug-2023.
Analyst best performing recommendations are on CYCC (CYCLACEL PHARMACEUTICALS).
The best stock recommendation documented was for CYCC (CYCLACEL PHARMACEUTICALS) at 3/7/2023. The price target of $10 was fulfilled within 3 days with a profit of $0.93 (8.51%) receiving and performance score of 28.36.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy
$41.84
$-9.78 (-18.95%)
1 years 8 months 29 days ago
(22-Jan-2024)
2/3 (66.67%)
$15.98 (61.79%)
1060
Buy
$40.14
$-11.48 (-22.24%)
$50.92
1 years 10 months 14 days ago
(07-Dec-2023)
3/3 (100%)
$15.12 (60.43%)
1094
Hold
$50
2 years 1 months 20 days ago
(01-Sep-2023)
1/1 (100%)
$21.24 (73.85%)
2008
Hold
$37.53
$-14.09 (-27.30%)
$43.39
2 years 7 months 8 days ago
(13-Mar-2023)
5/5 (100%)
$8.06 (27.35%)
962
Buy
$44
$-7.62 (-14.76%)
$46.97
2 years 8 months 8 days ago
(13-Feb-2023)
4/4 (100%)
$13.71 (45.26%)
1264
What Year was the first public recommendation made by James Edwardes Jones?
